Drug Trial Radar · NCT07656415
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
159
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Aug 2029
Study completion Aug 2030
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.
Conditions
- Sickle Cell Disease
Interventions
Mitapivat Matched PlaceboDrug
Tablets
MitapivatDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects who are Transfusion Free From Week 4 Through Week 52Time frame: Week 4 through Week 52
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana · Recruiting
The Cancer and Hematology Centers (CHC)
Grand Rapids, Michigan · Recruiting
Southern Specialty Clinic
Flowood, Mississippi · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.